Lower doses of CagriSema produced about 21% weight loss over 68 weeks in REDEFINE 9, a phase 3 trial Novo Nordisk announced on November 14, 2026 alongside its publication in The Lancet Diabetes & Endocrinology.12 The 1.0 mg / 1.0 mg dose, less than half the 2.4 mg / 2.4 mg dose Novo has filed with the FDA, averaged 21.0% against 2.0% on placebo.13
That is good news for the drug. It is also the more flattering of the trial's two readings. Counting everyone randomized, including people who stopped, the lower doses beat placebo by about 14 to 15 percentage points, against 17.3 for the full dose in REDEFINE 1.45 The trial was small. It enrolled 309 people and was not built to tell its two doses apart.34
What did REDEFINE 9 test?
REDEFINE 9 tested whether CagriSema works at two doses below the one Novo filed for approval. CagriSema is a weekly injection that combines cagrilintide, a long-acting copy of the appetite hormone amylin, with semaglutide, the GLP-1 drug in Wegovy, in one fixed 1:1 dose.
The trial randomized 309 adults without diabetes who had obesity, or overweight with at least one weight-related condition, at 24 sites in Canada, France, Germany, the UK and the US.3 Average starting weight was about 241 pounds.4 People were assigned to 1.7 mg / 1.7 mg (104 people), 1.0 mg / 1.0 mg (103) or placebo (102), and everyone got diet and activity counseling.3 Each dose had its own placebo group, and the two placebo groups were pooled for reporting.34 The 1.7 mg arm reached its dose over 12 weeks and the 1.0 mg arm over 8.3 Novo funded the trial and supplied the drug.3
| Measure at week 68 | CagriSema 1.0 / 1.0 mg (REDEFINE 9) | CagriSema 1.7 / 1.7 mg (REDEFINE 9) | Placebo (REDEFINE 9) | CagriSema 2.4 / 2.4 mg (REDEFINE 1) | Placebo (REDEFINE 1) |
|---|---|---|---|---|---|
| People randomized | 103 | 104 | 102 | 2,108 | 705 |
| Weight change, if everyone stayed on treatment | -21.0% | -20.7% | -2.0% | -22.7% | -2.3% |
| Weight change, counting everyone randomized | -18.6% | -19.4% | -4.6% | -20.4% | -3.0% |
| Difference from placebo, counting everyone | 13.9 points | 14.7 points | 17.3 points | ||
| Lost at least 20%, if everyone stayed on | 48.3% | 51.3% | 2.7% | not compared here | |
| Stopped for side effects | 4.9% | 2.9% | 4.9% | 5.9% | 3.5% |
REDEFINE 9 figures come from reports of the Lancet paper and Novo's release; REDEFINE 1 figures come from its 2025 NEJM paper.345 The two trials enrolled different people in different numbers, so the columns sit side by side for scale and are not a head-to-head test.
How much weight did people lose on the lower doses?
People on either lower dose lost about a fifth of their body weight if they stayed on treatment, and a little under a fifth counting everyone. On the measure that assumes everyone kept taking the drug, the 1.0 mg group lost 21.0% and the 1.7 mg group 20.7%, against 2.0% on placebo.34 Counting everyone, including those who stopped or took other weight-loss treatment, the figures were 18.6% and 19.4% against 4.6%.4
Nearly everyone on the drug lost a meaningful amount. About 95% of each group lost at least 5% of their weight, and roughly half lost at least 20%, against under 3% on placebo.3 Waists shrank by about 6.8 to 6.9 inches on the drug and 1.4 inches on placebo.3
Both arms now have published figures. When Novo first disclosed REDEFINE 9 at its September 21 investor day, it gave the 21.0% figure for the 1.0 mg dose only, and our page on when CagriSema could be approved recorded that the 1.7 mg arm had no number.67 The paper supplies it, along with the randomized total.3
Why are there two different weight loss numbers?
Trials have to decide what to do about people who stop the drug partway through, and that choice is called an estimand. The efficacy estimand asks what would have happened if everyone had stayed on treatment, and Novo also calls it the trial product estimand. The treatment-regimen estimand counts every person randomized, the way a real prescription plays out, and also goes by treatment policy.5
Novo's headline uses the first, as its September announcement did, and it is the larger of the two.16 In REDEFINE 1, the FDA filing trial, the regimen version was the primary result: 20.4% against 3.0% on placebo.5 So the fairer comparison for REDEFINE 9 is 18.6% and 19.4%, not 21%.
The placebo group also lost more in REDEFINE 9 than in REDEFINE 1: 4.6% counting everyone, against 3.0%, probably helped by the counseling.45 That shrinks the drug's own share. On the regimen measure, the lower doses beat placebo by 13.9 and 14.7 points, against 17.3 for the full dose in REDEFINE 1.45
Is 1.0 mg as good as 1.7 mg?
The trial cannot say. It was not powered to compare its two doses, meaning it was too small to detect a difference between them reliably.4 The 1.0 mg group lost slightly more on the stay-on-treatment measure and slightly less counting everyone, and both gaps are under one percentage point.4
Fewer people stopped for side effects on 1.7 mg (2.9%) than on 1.0 mg (4.9%), and the placebo group's rate matched the 1.0 mg group's at 4.9%.3 With about 100 people per arm, each of those percentages rests on a handful of people.
Does a lower dose mean fewer side effects?
The trial suggests the lower doses were well tolerated, and the clearest sign is the dropout rate. Only 2.9% and 4.9% stopped because of side effects, no more than on placebo. In REDEFINE 1, 5.9% stopped on 2.4 mg.35 Most side effects were gastrointestinal and mild to moderate, and no deaths were reported.3 Some side effect was recorded in 99% of the 1.7 mg group, 95% of the 1.0 mg group and 91% on placebo.3
What we could not find were rates for individual stomach symptoms. In REDEFINE 1, 79.6% of people on the full dose had gastrointestinal side effects against 39.9% on placebo, and those figures are the ones a lower dose is supposed to improve.5 The reports of REDEFINE 9 we could read did not give nausea, vomiting or constipation rates, and the paper itself would not load for us.234 Until those numbers are checked, "easier on the stomach" is a hope supported by the dropout figures and not yet a measured result.
Does this change what the FDA is deciding?
No. Novo's application covers the 2.4 mg / 2.4 mg dose, filed in December 2025 on the strength of REDEFINE 1 and REDEFINE 2, and Novo still expects a decision in the fourth quarter of 2026.78 No public decision date has been set.7
REDEFINE 9 matters for what happens after a decision. Many people in REDEFINE 1 never reached the top dose: only 57.4% of the CagriSema group was on 2.4 mg / 2.4 mg at week 68.5 The 20.4% headline already included people held at lower doses. REDEFINE 9 shows what those doses do when they are the plan from the start, and Novo's September announcement framed the trial around people who do not receive or stay on the highest dose.6 Whether any lower strength reaches a label depends on what Novo files and what the FDA accepts, and neither has been announced.
What is known, and what is not?
What REDEFINE 9 shows:
- Both lower doses beat placebo clearly on weight, waist size and the share of people losing 5%, 10%, 15% and 20%.34
- Counting everyone, weight fell 18.6% on 1.0 mg and 19.4% on 1.7 mg over 68 weeks.4
- Few people stopped for side effects, no more than on placebo.3
- The results are peer-reviewed, published in The Lancet Diabetes & Endocrinology.2
What it does not show:
- Whether 1.0 mg and 1.7 mg differ. The trial was not designed to tell.4
- How the lower doses compare with 2.4 mg in the same people. No trial has randomized them against each other.
- Rates of nausea, vomiting and other stomach effects, in anything we could read.34
- How the doses perform in people with type 2 diabetes, who were excluded.3
- What happens to weight after people stop.
What does this change for someone with a vial?
The trial tells you what Novo's CagriSema did at fixed, measured doses made to drug manufacturing standards.3 A research-market vial reproduces that only if it holds both peptides at the amounts on the label.
Gray-market CagriSema is sold as a blend, usually labeled 5/5 or 10/10 mg. Our November 7 price read found 24 listings, with 10 mg vials running $79.00 to $120.00 across 12 stores.8 We found no independent blind testing of the blend itself. Finnrick, a lab service that buys peptides anonymously and publishes results, lists cagrilintide on its own: 107 passes and 91 fails across 47 sellers between April 2025 and November 2, 2026, as of November 15.9 We did not find blend results on that page. A blend has two ingredients that can each be off, and a vial short on either one will not reproduce the trial's results.
The careful version looks the same as for any vial: a per-lot certificate of analysis with the lot number printed on the vial, a seller on our vendor list with no open FDA warning letter, an independent test of the first vial, and the dose calculator run on the concentration the test found. Our CagriSema page carries the full trial record, and the cagrilintide and semaglutide comparison sets out what each half of the blend did alone.
What happens next?
The FDA decision on the 2.4 mg / 2.4 mg dose is the next date, expected by the end of 2026.78 REDEFINE 11, another phase 3 trial of the full dose, is due to report in the first half of 2027, and Novo has planned a higher-dose trial pairing 2.4 mg of cagrilintide with 7.2 mg of semaglutide.10
For REDEFINE 9 itself, the open item is the full side effect table in the Lancet paper. Our earlier piece on CagriSema's head-to-head loss to tirzepatide covers the other recent trial that shaped how the drug will be positioned.
Common questions
Does lower-dose CagriSema work?
Yes, in REDEFINE 9. Over 68 weeks, 1.0 mg / 1.0 mg and 1.7 mg / 1.7 mg produced 18.6% and 19.4% weight loss counting everyone randomized, against 4.6% on placebo.
Where does the 21% figure come from?
Novo's November 14, 2026 release. It is the 1.0 mg result under the efficacy estimand, a model that assumes everyone stayed on treatment. Counting everyone, the figure is 18.6%.
How does that compare with the full 2.4 mg dose?
Close, but not identical. In REDEFINE 1, the full dose produced 20.4% counting everyone, 17.3 points better than placebo. The lower doses in REDEFINE 9 beat placebo by 13.9 and 14.7 points. They were different trials.
Is 1.0 mg better than 1.7 mg?
Unknown. The trial was not powered to compare the two doses. The results differed by less than one percentage point in each direction.
Were there fewer side effects on the lower doses?
Fewer people stopped because of them. Dropouts for side effects were 2.9% and 4.9%, no more than placebo. REDEFINE 1 recorded 5.9% on 2.4 mg. Individual stomach symptom rates were not in the reports we could read.
How many people were in REDEFINE 9?
309 adults without diabetes: 104 on 1.7 mg, 103 on 1.0 mg and 102 on placebo, at 24 sites in five countries.
Was REDEFINE 9 peer-reviewed?
Yes. It was published in The Lancet Diabetes & Endocrinology in November 2026, alongside its presentation at ObesityWeek in Washington.
Who paid for the trial?
Novo Nordisk funded it and supplied the drug. The lead author is Sean Wharton of the University of Toronto.
Is CagriSema approved?
No. It is not approved anywhere. Novo filed the 2.4 mg / 2.4 mg dose with the FDA in December 2025 and expects a decision in the fourth quarter of 2026.
Will the FDA approve a lower dose?
Not in the current application. It covers 2.4 mg / 2.4 mg only. Novo has not announced a filing for 1.0 mg or 1.7 mg.
Why did the placebo group lose 4.6%?
Everyone got diet and activity counseling, and that figure counts people who left placebo and took other weight-loss treatment. It is higher than REDEFINE 1's 3.0%.
What are the two estimands?
Two ways of handling people who stop treatment. The efficacy estimand assumes everyone stayed on the drug. The treatment-regimen estimand counts everyone randomized, whatever they did.
Did most people in REDEFINE 1 reach the full 2.4 mg dose?
Just over half. Only 57.4% of the CagriSema group were on 2.4 mg / 2.4 mg at week 68, and the 20.4% result counts everyone assigned to that group.
Did REDEFINE 9 include people with diabetes?
No. People with diabetes were excluded. CagriSema's diabetes trials are the separate REIMAGINE program.
Is gray-market CagriSema the same as the trial drug?
Only if a vial holds both peptides at the stated amounts. Finnrick's cagrilintide testing, as of November 15, 2026, records 91 fails among 198 completed results, so a per-lot certificate and a test of the first vial matter.
What comes next for CagriSema?
The FDA decision on the full dose, expected by the end of 2026. REDEFINE 11 reports in the first half of 2027, and a higher-dose trial is planned.
Sources
- Novo Nordisk. Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology. November 14, 2026, via PR Newswire. prnewswire.com.
- Wharton S, et al. REDEFINE 9 trial report. The Lancet Diabetes & Endocrinology, November 2026. sciencedirect.com.
- Securities.io. Novo Nordisk Reports About 21% Weight Loss With Lower CagriSema Doses. November 14, 2026. securities.io.Read at source. Independent reporting that summarizes the Lancet paper and Novo's release, so it is a reproduction of the trial figures and not the paper itself. Source of the 309 randomized and per-arm counts, eligibility, 24 sites in five countries, the 12-week and 8-week dose escalation, counseling, funding, completion (291 completed, 254 on treatment at week 68), efficacy-estimand weight change and placebo-adjusted differences (18.8 and 19.0 points), the 5% and 20% responder rates, waist change (17.2, 17.5 and 3.6 cm), any adverse event (99%, 95%, 91%), discontinuation for adverse events, no deaths, and the note that the 1.0 mg figure was first disclosed on September 21, 2026. Gives no gastrointestinal event rates. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Biotech Reality. Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026. November 15, 2026. biotechreality.com.Read at source. Independent write-up of Novo's release, so a reproduction. Source of the treatment-regimen estimand figures (19.4%, 18.6%, 4.6%) and differences (14.7 and 13.9 points), baseline weight of 109.5 kg (about 241 pounds), and the statement that the trial was not powered to compare the two doses. Its efficacy-estimand and responder figures match note 3. Gives no gastrointestinal event rates. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine, June 22, 2025. doi:10.1056/NEJMoa2502081. nejmgroup-production.org.Read at source (NEJM media center PDF). Source of 3,417 randomized (2,108 CagriSema, 705 placebo), weight change of -20.4% against -3.0% (treatment policy, difference 17.3 points) and -22.7% against -2.3% (trial product), 57.4% on the maximum dose at week 68, discontinuation for adverse events of 5.9% against 3.5%, and gastrointestinal adverse events of 79.6% against 39.9%. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Novo Nordisk. Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. Company announcement, September 21, 2026. novonordisk.com.Read at source. Company document. Describes REDEFINE 9 as a 68-week trial of 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg against placebo and reports 21.0% against 2.0% with the primary superiority endpoint met, based on the efficacy estimand, with no figure for the 1.7 mg arm. Source of the company's framing that not all patients receive or stay on the highest dose. ↩ ↩ ↩
- Peptide Decoding. When Will CagriSema Be Approved? What Novo Has Filed. peptidedecoding.com/guides/cagrisema-fda-decision.
- Peptide Decoding. CagriSema compound page. peptidedecoding.com/peptides/cagrisema.Our own page, read November 15, 2026. Source of the approval status, the 2.4 mg / 2.4 mg trial dose, the 5/5 and 10/10 vial labeling, and the price figures (24 listings, last read November 7, 2026; 10 mg vials $79.00 to $120.00 across 12 stores). Novo's Q4 2026 decision expectation is restated in its November 15, 2026 ObesityWeek release on REDEFINE 1 (prnewswire.com, read at source, company document). ↩ ↩ ↩
- Finnrick. Cagrilintide test results. finnrick.com/products/cagrilintide.Read at source November 15, 2026. Independent testing service. Its history table lists 200 cagrilintide tests (the page header says 209) from 47 sellers, first dated April 20, 2025 and latest November 2, 2026: 107 pass, 91 fail, 2 incomplete. The page covers cagrilintide alone; we did not see CagriSema blend results on it. Seller rankings are not reproduced here. ↩
- Novo Nordisk. Company announcement on REDEFINE 4, February 23, 2026. novonordisk.com.Read at source. Company document. Source of REDEFINE 11 (2.4 mg / 2.4 mg) reporting in the first half of 2027 and the planned 2.4 mg / 7.2 mg higher-dose phase 3 trial. Those plans date from February and may have changed. ↩
Citing this page. Peptide Decoding. Does Lower-Dose CagriSema Work? What REDEFINE 9 Actually Shows. Trial figures from reports of the REDEFINE 9 paper in The Lancet Diabetes & Endocrinology and Novo Nordisk's release of November 14, 2026, and the REDEFINE 1 paper in NEJM (2025); price figures from our November 7, 2026 capture; testing figures from Finnrick as of November 15, 2026. Reviewed November 15, 2026. https://peptidedecoding.com/news/cagrisema-redefine-9-lower-doses

